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ABSTRACT Genetic and biochemical studies on enzymes
known to be involved in regulating DNA supercoiling yield a com-
plex spectrum of effects on the Escherichia coli SOS system. Pre-
vious studies indicated that only inhibition of DNA gyrase by an-
tibiotics that act on the DNA gyrase A subunit results in turning
on the E. coli SOS system. Here we show that coumermycin, an
antibiotic that acts on the DNA gyrase B subunit, can also induce.
Like nalidixic acid induction, coumermycin induction is depen-
dent on the recBC DNase. In both cases induction apparently re-
sults from a response of the cell to the DNA gyrase-inhibitor com-
plex rather than just the loss of DNA gyrase activity. However,
unlike induction by the DNA gyrase A-specific antibiotics, cou-
mermycin induction also requires the recF gene product. This
demonstrates a functional relationship between DNA gyrase and
the recF gene product.
DNA gyrase catalyzes the introduction of negative superhelical
twists into double-stranded closed-circular DNA in an ATP-de-
pendent reaction (1); in the absence of ATP, gyrase relaxes su-
percoiled DNA (for reviews see refs. 2 and 3). The enzyme is
composed of two subunits, originally identified as targets for
two types of antibiotics. The DNA gyrase A subunit is the tar-
get of nalidixic and oxolinic acid (4, 5) and has the breakage
rejoining activity of the enzyme. In the presence of nalidixic
acid DNA gyrase forms a relaxation complex with DNA. The
DNA gyrase B subunit mediates energy transduction required
in the supercoiling reaction and is the target for novobiocin and
coumermycin Al (6). Inhibition of DNA gyrase by any of these
antibiotics threatens the survival of Escherichia coli because
DNA synthesis is arrested (7, 8).
A halt in DNA synthesis leads to the coordinated induction
of numerous recA-dependent phenomena, termed SOS func-
tions (for a recent review see ref. 9), which promote the sur-
vival of E. coli and its phages. SOS functions include an error-
prone DNA repair, prophage induction, and inhibition of recBC
DNase-mediated DNA degradation. The induction of these
phenomena depends on the activation of the constitutively made
recA protein to act as a protease and cleave its own repressor
(10) and other repressors (11, 12).
One would expect that interference with DNA gyrase would
lead to turning on the SOS system. In fact, treatment of E. coli
with nalidixic or oxolinic acid (gyrase A-specific antibiotics) leads
to the immediate turn-on of the SOS system (13). However, we
did not observe turn-on by novobiocin, a gyrase B-specific an-
tibiotic (14), and others have reported no SOS induction when
E. coli was treated with other gyrase B-specific antibiotics (cou-
mermycin and chlorobiocin) or when a gyrase B temperature-
sensitive mutant was incubated at the restrictive temperature
(15, 16). Here, we have reexamined this discrepancy by using
Table 1. E. coli strains used
Strain Relevant genotype* Source
AB1157 Wild type M. Oishi
CS2369 gyrB- (couR) This studyt
JC9239 recF- A. J. Clark
M01518 recB- M. Oishi
JC8679 recB- recC- sbcA- R. Kolodner
*All strains are derivatives of AB1157 and contain the following ge-
netic markers: thr-1, leu-6, lacYl,gaIK2, ara-14, xyl-5, mtl-1,proA2,
his, argE3, str-31, tsx-33, and supE44.
t Constructed by phage P1 transduction ofthegyrB- (coumermycin re-
sistance) mutation fromE. coli strain N1748, obtainedfrom N. R. Coz-
zarelli, to AB1157.
a more sensitive assay for recA induction that we have devel-
oped.
MATERIALS AND METHODS
Bacterial strains used in this study are listed in Table 1. All ex-
periments were carried out with E. coli cells grown at 370C with
shaking in supplemented minimal medium, containing ampi-
cillin at 25 ,ug/ml. Details of procedures used for induction as-
says can be found in ref. 16. Data are plotted as anthranilate
synthase (ASase) activity per ml of culture. However, specific
activities parallel these total activity values. The relative merits
of different ways of plotting these data will be discussed else-
where (16).
To follow DNA synthesis cells were grown at 37C with shak-
ing in supplemented minimal medium containing ampicillin at
25 ,g/ml and thymidine at 1 pug/ml to a density of 1 x 108 cells
per ml. At that time thymidine was added to give an additional
5 ,ug/ml along with deoxyadenosine at 200 tg/ml and [3H]thy-
midine [45 Ci/mmol; Amersham (1 Ci = 3.7 x 1010 Bq)] at 2
juCi/ml and the incubation was continued. Twelve minutes later
portions of the culture were treated with the various DNA gy-
rase inhibitors.
All antibiotic solutions were stored at 40C. Nalidixic acid and
novobiocin were obtained from Sigma. Oxolinic acid was a gift
from Warner-Lambert (Ann Arbor, MI). Nalidixic acid and ox-
olinic acid were dissolved in 50 mM NaOH at 10 and 1 mg/ml,
respectively. Novobiocin was made up at 10 mg/ml in water.
Coumermycin was obtained from Bristol Laboratories (Syr-
acuse, NY) or purchased from Godfrey Science and Design
(Syracuse, NY) and dissolved in dimethyl suffoxide (Me2SO) at
5 mg/ml. Different batches obtained over a 5-year period be-
haved identically. Because coumermycin is typically used at 20
jug/ml, use of a Me2SO stock solution results in a final Me2SO
concentration of 0.4%. Me2SO alone at this concentration has
no effect on the constitutive activity of the recA-trp gene fu-
Abbreviations: ASase, anthranilate synthase; Me2SO, dimethyl sulf-
oxide.
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sion. Me2SO alone is not an inducer. We examined the effect
of Me2SO concentrations up to 2.5% on the activity of various
inducing agents. No effect was seen except for coumermycin,
for which a progressive inhibition of induction activity is seen
as the Me2SO concentration is increased. The kinetics of cou-
mermycin induction are unaltered by Me2SO, but the inhibi-
tion may explain why others in the past have been unable to
observe coumermycin induction. It is possible to use aqueous
stock solutions of coumermycin, but these are unstable to pro-
longed storage.
RESULTS
Earlier studies of recA induction have relied mainly on tedious
indirect assays. To circumvent the difficulties associated with
these systems we constructed a gene fusion between the recA
control region and the trpED genes on pBR322 derivative plas-
mid, pCS16. The fusion region of pCS16 is shown in Fig. 1.
This system closely mimics the known behavior of the recA op-
eron in vivo (unpublished data). SOS induction is monitored by
assaying the production of ASase, the product of the trpED
genes. Different strains carrying pCS16 show 2- to 4-fold vari-
ation in ASase activity. These differences are not significant for
any of the results described below.
The recA-trp-containing plasmid, pCS16, was used to trans-
form the various E. coli strains listed in Table 1 and SOS in-
ducibility by various DNA gyrase inhibitors was measured. When
we examined the inducibility of recA with DNA gyrase inhib-
itors in a wild-type E. coli strain the expected gyrase A-depen-
dent induction of recA was observed. In addition we found that
coumermycin Al, a gyrase B-specific antibiotic, also turned on
recA synthesis (Fig. 2A). The kinetics of turn-on with cou-
mermycin were distinctly slower than that observed with gy-
rase A-specific antibiotics and other inducers. This is not due
to a delay in uptake of the drug or to the speed at which DNA
synthesis is turned off. We find coumermycin, just like gyrase
A-specific antibiotics, is able to turn off DNA synthesis within
5 min after addition to E. coli cultures (Fig. 3).
It is not clear why others in the past have been unable to
observe coumermycin induction. The relatively weak response
and slow kinetics, while easily detected by our fusion tech-
nique, may have been difficult to see by less sensitive tech-
niques. Other possible explanations are discussed in Materials
and Methods.
It was disturbing that a typical dose of coumermycin (20 ,ug/
ml) induced recA synthesis, whereas no induction was ob-
served with typical doses (100-300 ,ug/ml) of novobiocin (Fig.
2). This, plus the fact that temperature-sensitive gyrase B mu-
tants failed to show induction at the restrictive temperature (15),
raised the possibility that SOS induction by coumermycin is not
due to its action on gyrase B. However, no recA induction was
observed with two different, proven gyrase B coumermycin-re-
sistant mutants. Results obtained with one of these mutants are
shown in Fig. 2B. This means coumermycin-mediated recA in-
duction must be acting via the gyrase B subunit. Coumermycin
induction of recA does not occur in recA or lexA- strains (data
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FIG. 2. Induction of recA-directed ASase synthesis in wild-type and
gyrB- (coumermycin-resistant) E. coli. One unit (U) ofASase catalyzes
formation of 1 nmol ofanthranilic acidper 10min at 37C. E. coli strain
AB1157 (A) and CS2369 (B) were grown to 1 x 108cells permlandtreated
with coumermycin at 20 ug/ml (e), nalidixic acid at 40 yg/ml (A), ox-
olinic acid at 5 Ag/ml (A), or novobiocin at 100 ug/ml (o). o, Untreated
control.
by normal activation of recA proteolytic activity.
Why is there no SOS induction with typical novobiocin doses?
We examined the effect of typical novobiocin doses on the abil-
ity of other drugs to induce recA. In every case roughly 2-fold
inhibition of recA synthesis was observed. Similar inhibition is
observed with the other DNA gyrase inhibitors in genetic back-
grounds where they themselves are not inducers. Such a partial
inhibition implies that gyrase activity is involved (but not re-
quired) in some stage of recA expression.
Guided by the observations of R. Menzel and M. Gellert
that very high doses of novobiocin induce recA protein (per-
sonal communication), we studied the effect of novobiocin in
our system at concentrations all the way from 100 ,ug/ml to 2.5
mg/ml. Around 1 mg/ml novobiocin a small amount of recA
induction is observed. This shows that failure of typical no-
vobiocin doses to induce is due not to some qualitative differ-
ence between novobiocin and coumermycin but merely to the
fact that novobiocin inhibition of recA synthesis masked its in-
duction. Presumably with coumermycin and other stronger
gyrase inhibitors induction is so rapid and pronounced that the
simultaneous inhibition goes unnoticed.
One is still left with the puzzle that inhibition by gyrase A-
or gyrase B-specific antibiotics leads to recA induction, whereas
no induction was seen in a strain with temperature-sensitive














FIG. 3. Inhibition ofDNA synthesis by antibiotics that act onDNA
gyrase. E. coli strain AB1157 was grown to 1 x 108 cells per ml and
treated (arrow) with coumermycin at 20 pg/ml (e), nalidixic acid at 40




FIG. 1. A fusion between theE. coli recA operon and trpED genes.
TheBamH/EcoRI DNA fragment shown is cloned in pBR322. o/p, Op-
erator-promoter.
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ditional temperature-sensitive gyrase B mutant (17) and a tem-
perature-sensitive gyrase A mutant (18), using our sensitive as-
say. No induction was seen in either case, even after prolonged
incubation at the restrictive temperature. These results imply
that elimination of gyrase activity is insufficient to cause in-
duction of recA. Some property of gyrase-inhibitor complexes,
perhaps their inability to dissociate from DNA, must be re-
sponsible for generating an induction signal. In agreement with
previous results (15), we observe the curious fact that gyrase-
specific antibiotics were still able to induce in temperature-sen-
sitive gyrase mutants at the restrictive temperature. This may
reflect stabilization of gyrase by the bound antibiotics or simply
that thermal inactivation of gyrase activity leaves unaltered the
property of gyrase-inhibitor complexes required for induction.
We tested the involvement of various recombination path-
ways (19) on recA induction mediated by gyrase-antibiotic
complexes. As had been reported previously (13), nalidixic acid-
mediated SOS induction is not seen in recB- recC- cells (Fig.
4A). Similarly, coumermycin-mediated induction is also not seen
(Fig. 4a). Recombinational proficiency can be restored to recB-
recC- cells by either the introduction of the phage A recom-
bination system or nonallelic suppressor (sbcB- or sbcA-) mu-
tations. These are known to restore SOS induction by nalidixic
acid in recB- recC- cells (20, 21). The results shown in Fig. 4B
indicate that, when cells lacking the recBC DNase carry an ad-
ditional sbcA- mutation, SOS induction by both coumermycin
and nalidixic acid is once again observed.
Although the genetic manipulations described above restore
the recombinational proficiency of recB- recC- cells, they do
not restore recBC DNase activity. Apparently, the role of that
enzyme can be replaced by A exonuclease or, in sbcA- cells, by
exonuclease VIII (22). Both of these nucleases are double-strand
5'-3' exonucleases. Presumably it is this activity of the recBC
DNase that is important in turning on the E. coli SOS system
after both gyrase A and gyrase B inhibition. The situation must
be somewhat different in recB- recC- sbcB- cells. Here the
loss of exonuclease I, a single-strand exonuclease, is believed
to channel recombination intermediates into the recF recom-
binational pathway. We cannot examine recA induction with
pCS16 in recB- recC- sbcB- cells because they are unable to
maintain plasmids (23). Instead we chose to examine the recF
dependence of induction by gyrase inhibitors.
Coumermycin induction is not seen in recF cells (Fig. 5),
even when these cells are studied for extended periods of time.
In contrast, nalidixic acid induction is unaffected by recF- mu-
tations. The specific requirement for the recF gene product in
SOS induction by a gyrase B but not a gyrase A inhibitor implies
that the recF gene product has a unique interaction with gyrase
B-coumermycin complexes. A recA induction that is totally de-
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FIo. 4. Induction of recA-directed ASase synthesis in E. coli recB-
recC- and recBW recC- sbcB- strains. E. coli strains M01518 (A) and
JC8679 (B) were grown to 1 x 108 cells per ml and treated with cou-







FIG. 5. Induction of recA-directed ASase synthesis in an E. coli
recF- strain. E. coli strain JC9239 was grown to 5 x 107 cells per ml
and treated with coumermycin at 20 tg/ml (0), nalidixic acid at 40 Mg/
ml (v), or oxolinic acid at 5 qg/ml (A). o, Untreated control.
viously. The recF recombination pathway is considered to be
a minor pathway that normally functions only in the absence of
exonuclease I [sbcB gene product (24, 25)]. However, the recF
pathway appears to involve unique recombination intermedi-
ates; the importance of these needs to be assessed (26, 27). In
addition, recF cells are sensitive to ultraviolet irradiation and
there is evidence that the as-yet-unidentified recF gene prod-
uct plays a role in DNA repair (28). The association of gyrB and
.recF may provide a key to an essential role of the recF gene
product in DNA repair.
DISCUSSION
Changes in supercoiling are known to affect expression of var-
ious operons by altering transcription (29-32). Coumermycin
induction is not simply due to a direct effect of the drug on tran-
scription because of the recA, recBC, and recF dependence. In
addition, all the DNA gyrase inhibitors partially inhibit recA
expression when they are added to cells in which they do not
induce. This indicates that changes in supercoiling caused by
DNA gyrase inhibition result in down rather than up expression
of the recA operon. To induce the recA operon some specific
property of gyrase-inhibitor complexes is required and not
simply. inhibition of gyrase activity.
The very different kinetics and recF dependence of recA turn-
on resulting from gyrase A- and gyrase B-specific antibiotics
imply different induction mechanisms. In fact, when E. coli is
treated with gyrase A- or gyrase B-specific antibiotics very dif-
ferent things happen. In the former case, DNA replication is
rapidly inhibited (33) and the chromosome is rendered suscep-
tible to cleavage by protein denaturants, as in the behavior of
relaxation complexes (34). Drlica and colleagues (35) have ar-
gued-that the rapid halt of DNA synthesis is caused by inhi-
bition of gyrase molecules associated with replication forks rather
than those that appear to be distributed at intervals over the
chromosome. Nalidixic acid induction of the SOS system is rapid
and is almost certainly related to tight drug-gyrase-DNA com-
plexes. However, it is not clear whether all gyrase-antibiotic
complexes lead to induction or just those associated with rep-
lication forks.
Treatment of E. coli with gyrase B-specific antibiotics results
in relaxation of the chromosome even when DNA replication
is absent (36). This relaxation appears to be associated with the
inhibition of gyrase molecules distributed over the chromo-
A B
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some. Coumermycin treatment results in a slow decrease in the
rate of DNA synthesis, which reaches a plateau after 20 min.
This decrease parallels the loss in superhelical density. How-
ever, when we followed the coumermycin inhibition of total
DNA synthesis by continuous labeling (see Fig. 3) we did not
see the slow turn-off reported by Drlica and Snyder (36). They
measured the rate of DNA synthesis during a short labeling
pulse, whereas we measured the amount of stable DNA syn-
thesized. Thus the slowly decreasing DNA synthesis rate either
is due to a DNA repair synthesis or represents continual ini-
tiation and rapid degradation of newly synthesized DNA. Cou-
mermycin induction of recA shows the same kinetics as relax-
ation and the loss of this transient DNA synthesis.
Coumermycin-gyrase complexes do not render DNA sus-
ceptible to breakage. Why, then, does coumermycin induce,
and are all gyrase molecules potential targets for coumermycin
induction or just those associated with replication forks? One
possibility is that the motion of a replication fork is arrested
either by direct inhibition of gyrase there or by the first cou-
mermycin-gyrase complex the fork reaches. Transient DNA
synthesis and degradation at the stopped fork eventually result
in generation of an induction signal. Alternatively, gyrase-an-
tibiotic complexes distributed over the chromosome may be
recognized directly by other proteins, such as repair enzymes,
whose action results in DNA damage.
The recF dependence of coumermycin induction ought to be
the clue that allows the induction mechanism to be sorted out.
However, the absence of a proven function for recF is a serious
impediment. In E. coli the gyrB, recF, dnaN, and dnaA genes
are located in adjacent positions on the E. coli chromosome (37).
The dnaA gene product is involved in replication initiation, and
dnaA- mutants are hypersensitive to gyrase inhibitors (38). In
fact, it has been suggested that the close association of the recF
gene with genes known to be involved in DNA replication and
recombination implies a similar function for the recF gene product
(39). It is tempting to speculate that, like other genes located
in adjacent positions, the products of gyrB, recF, dnaN, and
dnaA actually form a functionally significant multiprotein com-
plex. Coumermycin inhibition of this target might then be the
step leading to recA induction.
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